|
|
|
|
|
|
|
Highlights from the 2024 Society of Urologic Oncology Annual Meeting |
|
|
|
|
| BCG Unresponsive Cancer in 2024 |
| Ashish Kamat, MD, MBBS |
| Ashish Kamat reviews advancements in managing BCG-unresponsive non-muscle-invasive bladder cancer. The discussion highlights key therapeutic options, including pembrolizumab (KEYNOTE-057 trial), nadofaragene firadenovec, and N-803 (nogapendekin alfa inbakicept), all showing varying levels of efficacy in achieving durable complete responses. |
|
|
|
|
|
| New Approaches to NMIBC Surgery
|
| Joseph Liao, MD
|
| Joseph Liao discusses advancements in non-muscle invasive bladder cancer (NMIBC) surgery, highlighting challenges in traditional transurethral resection of bladder tumor (TURBT), such as operator variability and incomplete resections. Enhanced imaging technologies like blue light cystoscopy (BLC) significantly improve cancer detection rates and accuracy, with sensitivity for BLC reaching 91% compared to 76% for white light cystoscopy. Innovations such as en bloc resection of bladder tumors (ERBT) show promise in reducing recurrence rates by achieving clearer margins, particularly for tumors ≤3 cm. |
|
|
|
|
|
| Keynote Lecture: Precision in Urothelial Carcinoma – FGFR
|
| Gopa Iyer, MD
|
| Gopa Iyer highlights the role of FGFR3 alterations in urothelial carcinoma across disease stages and the effectiveness of erdafitinib, an FGFR-targeted therapy. Erdafitinib has shown an overall survival benefit in FGFR3-altered metastatic urothelial carcinoma compared to chemotherapy, leading to FDA approval. Promising innovations like TAR-210, an intravesical erdafitinib delivery system, demonstrate potential in reducing systemic toxicity while maintaining efficacy, especially in non-muscle-invasive bladder cancer.
|
|
|
|
|
|
| Heterogeneity of Intermediate-Risk NMIBC |
| Sima Porten, MD, MPH |
| Sima Porten's presentation at SUO 2024 highlighted the significant clinical heterogeneity within intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Intermediate risk represents a middle ground between low-risk NMIBC, with <5% progression risk, and high-risk disease, with a 30% progression risk. This category includes a variety of clinical scenarios, stratified differently by guidelines such as AUA, EAU, and IBCG. |
|
|
|
|
|
|
|
|
|
|
| Emerging Perioperative Systemic Therapy |
| Jacqueline Brown, MD |
| Jacqueline Brown's presentation on emerging perioperative systemic therapy in muscle-invasive bladder cancer (MIBC) highlighted the evolving treatment landscape, focusing on chemotherapy, immunotherapy, and antibody-drug conjugates. Dr. Brown emphasized, the need to refine biomarkers like ctDNA for tailoring therapy and the importance of balancing efficacy with safety to preserve surgical outcomes. |
|
|
|
|
|
| Emerging Treatments and New Targets for Metastatic Urothelial Cancer
|
| Vadim Koshkin, MD
|
| Vadim Koshkin presents significant advancements in the treatment of metastatic urothelial carcinoma, emphasizing the transformative impact of antibody-drug conjugates such as enfortumab vedotin and trastuzumab deruxtecan. Targets like Nectin-4, HER2, Trop-2, and FGFR3 were highlighted, with EV showing impressive efficacy, particularly in combination with pembrolizumab. The presentation stressed the importance of exploring new drug combinations and systemic therapy intensification early in treatment to improve outcomes.
|
|
|
|
|
|
|
|
|
|
|
